CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

Authors: Mark H. O’Hara, Eileen M. O’Reilly, Gauri R. Varadhachary, Robert A. Wolff, Zev A. Wainberg, Andrew H. Ko, George A. Fisher, Osama E. Rahma, Jaclyn P. Lyman, Christopher R. Cabanski, Rosemarie Mick, Pier Federico Gherardini, Lacey J. Kitch, Jingying Xu, Theresa Samuel, Joyson Karakunnel, Justin Fairchild, Samantha Bucktrout, Theresa LaVallee, Cheryl Selinsky, Jacob E. Till, Erica L. Carpenter, Cécile Alanio, Katelyn T. Byrne, Richard O Chen, Ovid Trifan, Ute Dugan, Christine E. Horak, Vanessa M. Hubbard-Lucey, E. John Wherry, Ramy Ibrahim, Robert H. Vonderheide - The Lancet 2020 cited by 301